Pivikto 250mg Tablet
Marketer
Novartis India Ltd
Salt Composition
Alpelisib (250mg)
Overview Pivikto 250mg Tablet
Alpelisib 250mg tablets are indicated for managing specific breast cancer subtypes: hormone receptor-positive, HER2-negative, and PIK3CA-mutated advanced breast cancer, or cancer that has metastasized. This medication is administered concurrently with hormonal anti-cancer treatments. Administer Alpelisib 250mg with food, consistently at the same time daily for optimal efficacy. Dosage and frequency are determined by your oncologist based on your individual needs and may be adjusted. Strictly adhere to your physician's prescribed regimen; improper usage or overdose can lead to severe adverse reactions. Therapeutic benefits may not be immediately apparent, potentially taking weeks or months; discontinue use only under medical guidance. Common side effects include tiredness, reduced appetite, skin rashes, nausea, and diarrhea. Alpelisib can lower blood cell counts (red and white blood cells), increasing infection risk. Report any infection symptoms (fever, chills, weakness, bleeding, bruising, epistaxis) to your doctor promptly. Dizziness is possible; avoid driving or activities requiring alertness if affected. Prior to commencing treatment, disclose any pre-existing heart, liver, or kidney conditions, and all current medications, particularly anti-infectives, to your healthcare provider. Drug interactions are possible; inform your medical team of all medications. This medication is contraindicated during pregnancy and breastfeeding. Reliable contraception is crucial for both partners throughout treatment to prevent conception. A patient support program exists in India, managed by Tata 1mg; contact your doctor or call (1800-102-1618) for details.
Uses of Pivikto 250mg Tablet
Managing breast cancer
Major Benefits of Pivikto 250mg Tablet:
Follow your doctor's instructions precisely regarding dosage and treatment length for Pivikto 250mg Tablets. Ingest the tablets whole; do not crush, chew, or divide them. Take with food.
Common Side effects of Pivikto 250mg Tablet:
- Diarrhea
- Rash
- Increased glucose level in blood
- Nausea
- Vomiting
- Fatigue
- Increased creatinine level in blood
- Lymphocytopenia
- Increased gamma-glutamyltransferase
- Increased alanine aminotransferase
- Decreased hemoglobin
- Increased lipase in the blood
- Decreased appetite
- Stomatitis (Inflammation of the mouth)
- Weight loss
- Hypoglycemia (low blood glucose level)
- Decreased calcium level in blood
- Prolonged activated partial thromboplastin time (aPTT)
- Hair loss
How to use Pivikto 250mg Tablet:
Consume this medication precisely as your physician directs, adhering to both the prescribed dosage and treatment length. Ingest the entire tablet without chewing, crushing, or fracturing it. Pivikto 250mg Tablets should be administered with a meal.
How Pivikto 250mg Tablet works:
Pivikto 250mg tablets combat cancer by inhibiting the signaling pathways that stimulate cancerous cell proliferation, thus hindering tumor growth and metastasis.
SAFETY ADVICE
AlcoholCONSULT YOUR DOCTOR
Alcohol consumption alongside Pivikto 250mg Tablet lacks established safety data. Seek medical advice before combining them.
PregnancyCONSULT YOUR DOCTOR
Use of Pivikto 250mg tablets during pregnancy may pose risks. While human data is scarce, animal research indicates potential harm to a developing fetus. A physician will assess the advantages against possible dangers prior to prescribing. Seek medical advice before taking this medication.
Breast feedingCONSULT YOUR DOCTOR
Lactation and the use of Pivikto 250mg tablets are likely incompatible. Available data from human studies indicate a potential for the medication to transfer to breast milk, posing a risk to the infant.
DrivingCONSULT YOUR DOCTOR
Driving ability may be affected by Pivikto 250mg Tablet; however, the extent of this effect is currently unknown. Refrain from driving if you experience symptoms impairing concentration or reaction time.
KidneyCONSULT YOUR DOCTOR
Data regarding Pivikto 250mg Tablet use in patients exhibiting renal impairment is scarce. Physician consultation is advised.
LiverSAFE IF PRESCRIBED
Patients with hepatic impairment can safely use Pivikto 250mg tablets without requiring a dosage modification.
What if you forget to take Pivikto 250mg Tablet :
NA
Facts to Know About Pivikto 250mg Tablet
| Label | Value |
|---|---|
| Chemical Category | Proline-based compounds |
| Developing Habits | No. |
| Treatment Category | Cancer Medications |
3,018 People bought this recently